Cipolla Salvatore, Delli Carpini Flora, Catapano Pierluigi, De Santis Valeria, Volpicelli Antonio, Perris Francesco, Catapano Francesco
Department of Psychiatry, University of Campania "Luigi Vanvitelli", Largo Madonna delle Grazie 1, 80138 Naples, Italy.
Clin Pract. 2025 Mar 10;15(3):55. doi: 10.3390/clinpract15030055.
Treatment-resistant schizophrenia (TRS) poses significant therapeutic challenges due to persistent symptoms, poor adherence, and high relapse rates. Long-acting injectable (LAI) antipsychotics offer a promising approach, yet limited evidence exists regarding the combination of two LAI formulations. We report the case of a 62-year-old woman with TRS, characterized by recurrent hospitalizations and inadequate responses to oral and monotherapy treatments. During her latest hospitalization, she received alternating intramuscular administrations of haloperidol decanoate (100 mg/28 days) and aripiprazole (400 mg/28 days). The dual LAI strategy resulted in a marked improvement in psychotic symptoms, functional recovery, and treatment adherence, with no reported side effects. This case highlights the potential benefits of dual LAI therapy in managing TRS, particularly in patients with non-adherence to oral medications or limited response to standard treatments. Additional studies are required to evaluate the long-term effectiveness and safety of this innovative therapeutic approach.
难治性精神分裂症（TRS）由于症状持续、依从性差和复发率高而带来重大治疗挑战。长效注射（LAI）抗精神病药物提供了一种有前景的方法，但关于两种LAI制剂联合使用的证据有限。我们报告了一例62岁的难治性精神分裂症女性病例，其特点是反复住院，对口服和单一疗法治疗反应不佳。在她最近一次住院期间，她接受了癸酸氟哌啶醇（100mg/28天）和阿立哌唑（400mg/28天）的交替肌肉注射。双重LAI策略导致精神病症状、功能恢复和治疗依从性显著改善，且未报告有副作用。该病例突出了双重LAI疗法在管理难治性精神分裂症方面的潜在益处，特别是在那些不依从口服药物或对标准治疗反应有限的患者中。需要进一步研究来评估这种创新治疗方法的长期有效性和安全性。
